Do the dissociative side effects of ketamine mediate its antidepressant effects?

Luckenbaugh, David A., Niciu, Mark J., Ionescu, Dawn F., Nolan, Neal M., Richards, Erica M., Brutsche, Nancy E., Guevara, Sara, Zarate, Carlos A.·2014·Journal of Affective Disorders
DOI 10.1016/j.jad.2014.02.017

Cited by (284)

Items 101–200 of 284

  1. Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder—Initial Results of a Randomized, Controlled, Crossover, Pilot Study
    Logan K. Wink, Debra L. Reisinger, Paul S. Horn, Rebecca C. Shaffer, Kaela O’Brien, Lauren Schmitt, Kelli C. Dominick, Ernest V. Pedapati, Craig A. Erickson · 2020 · Journal of Autism and Developmental Disorders
  2. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression
    Ana Paula Jesus‐Nunes, Gustavo Carneiro-Gomes Leal, Fernanda S. Correia‐Melo, Flávia Vieira, Rodrigo Paixão Mello, Ana Teresa Caliman‐Fontes, Mariana V.F. Echegaray, Roberta Ferrari Marback, Lívia N. F. Guerreiro‐Costa, Breno Souza‐Marques et al. · 2022 · Human Psychopharmacology Clinical and Experimental
  3. Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions
    Kenji Hashimoto, Mingming Zhao, Tingting Zhu, Xingming Wang, Jianjun Yang · 2024 · Journal of Anesthesia and Translational Medicine
  4. Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents
    Piotr Popik, Małgorzata Hołuj, Tomasz Kos, Gabriel Nowak, Tadeusz Librowski, Kinga Sałat · 2017 · Neurotoxicity Research
  5. Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
    David S. Mathai, Sandeep Manel Nayak, David B. Yaden, Albert Garcia‐Romeu · 2023 · Psychopharmacology
  6. The antiaddictive effects of ibogaine: A systematic literature review of human studies
    RAFAEL GUIMARÃES DOS SANTOS, José Carlos Bouso, Jaime E. C. Hallak · 2017 · Journal of Psychedelic Studies
  7. Neurobiological biomarkers of response to ketamine
    Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus, Carlos A. Zarate · 2020 · Advances in pharmacology
  8. Can ‘floating’ predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression
    Elia E. Acevedo-Diaz, Grace W. Cavanaugh, Dede K. Greenstein, Christoph Kraus, Bashkim Kadriu, Lawrence Park, Carlos A. Zarate · 2020 · Journal of Psychiatric Research
  9. Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
    Rasmussen, Keith G. · 2016 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  10. LSD and ketanserin and their impact on the human autonomic nervous system
    Sebastian Olbrich, Katrin H. Preller, Franz X. Vollenweider · 2021 · Psychophysiology
  11. WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?: Editorial
    Newport, D. Jeffrey, Schatzberg, Alan F., Nemeroff, Charles B. · 2016 · Depression and Anxiety
  12. Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
    Joost J. Breeksema, Alistair R. Niemeijer, Bouwe Kuin, Jolien K. E. Veraart, Eric H. G. J. M. Vermetten, Jeanine Kamphuis, Wim van den Brink, Robert A. Schoevers · 2023 · Psychopharmacology
  13. Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
    Ezio Carboni, Anna Rosa Carta, Elena Carboni, Antonello Novelli · 2021 · Frontiers in Neuroscience
  14. Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
    Ioline D. Henter, RAFAEL TEIXEIRA DE SOUSA, Philip W. Gold, André R. Brunoni, Carlos A. Zarate, Rodrigo Machado‐Vieira · 2016 · Expert Review of Clinical Pharmacology
  15. Gray matter volume of rostral anterior cingulate cortex predicts rapid antidepressant response to ketamine
    Ana Lucía Herrera-Meléndez, Anna Stippl, Sabine Aust, Milan Scheidegger, Erich Seifritz, Isabella Heuser, Christian Otte, Malek Bajbouj, Simone Grimm, Matti Gärtner · 2020 · European Neuropsychopharmacology
  16. Lithium and Valproate Levels Do Not Correlate with Ketamine’s Antidepressant Efficacy in Treatment-Resistant Bipolar Depression
    Annie J. Xu, Mark J. Niciu, Nancy B. Lundin, David A. Luckenbaugh, Dawn Flosnik Ionescu, Erica M. Richards, Jennifer L. Vande Voort, Elizabeth D. Ballard, Nancy E. Brutsché, Rodrigo Machado‐Vieira et al. · 2015 · Neural Plasticity
  17. Ketamine-induced regulation of TrkB-GSK3β signaling is accompanied by slow EEG oscillations and sedation but is independent of hydroxynorketamine metabolites
    Samuel Kohtala, Wiebke Theilmann, Marko Rosenholm, Heidi Kaastrup Müller, Paula S. Kiuru, Gregers Wegener, Jari T. Yli‐Kauhaluoma, Tomi Rantamäki · 2019 · Neuropharmacology
  18. Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite
    Brendan D. Hare, Santosh Pothula, Ralph Dileone, Ronald S. Duman · 2020 · Neuropharmacology
  19. Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
    Hugo Bottemanne, Lucie Berkovitch, Christophe Gauld, Alexander Balcerac, Liane Schmidt, Stéphane Mouchabac, Philippe Fossati · 2023 · Neuroscience & Biobehavioral Reviews
  20. Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
    Marion Rame, Dorian Caudal, Esther Schenker, Per Svenningsson, Michael Spedding, Thérèse M. Jay, Bill P. Godsil · 2017 · PLoS ONE
  21. A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects
    Hannah Hartland, Kimia Mahdavi, Luke A. Jelen, Rebecca Strawbridge, Allan Hunter Young, Laith Alexander · 2023 · Journal of Psychopharmacology
  22. Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
    Rae R. Matsumoto, Linda Nguyen, Cory Weaver, K. Cramér, Scott Pollard, Patrick J. Marshalek · 2015 · Neuropsychiatric Disease and Treatment
  23. Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report.
    Jae Lee, Puneet Narang, Manasa Enja, Steven Lippmann · 2015 · Europe PMC (PubMed Central)
  24. Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy
    Basant Pradhan, Tapan Parikh, Ramkrishna D. Makani, Madhusmita Sahoo · 2015 · Depression Research and Treatment
  25. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence
    Orly Lipsitz, Roger S. McIntyre, Nelson B. Rodrigues, Yena L. Lee, Hartej Gill, Mehala Subramaniapillai, Kevin Kratiuk, Flora Nasri, Rodrigo Barbachan Mansur, Joshua Daniel Rosenblat · 2020 · CNS Spectrums
  26. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study
    Adam Włodarczyk, Wiesław Jerzy Cubała, Maria Gałuszko‐Węgielnik, Joanna Szarmach · 2021 · Medicine
  27. Disembodiment and Affective Resonances in Esketamine Treatment of Depersonalized Depression Subtype: Two Case Studies
    Pietro Sarasso, Martina Billeci, Irene Ronga, F. Raffone, Vassilis Martiadis, Gilberto Di Petta · 2024 · Psychopathology
  28. Interaction of Sex and Age on the Dissociative Effects of Ketamine Action in Young Healthy Participants
    Birgit Derntl, Jonas Hornung, Zümrüt Duygu Şen, Lejla Čolić, Mengxiang Li, Martin Walter · 2019 · Frontiers in Neuroscience
  29. Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial
    Rodrigo Paixão Mello, Mariana V.F. Echegaray, Ana Paula Jesus‐Nunes, Gustavo Carneiro-Gomes Leal, Guilherme Moreira Magnavita, Flávia Vieira, Ana Teresa Caliman‐Fontes, Manuela Telles, Lívia N. F. Guerreiro‐Costa, Breno Souza‐Marques et al. · 2021 · Journal of Psychiatric Research
  30. The antidepressant effect and safety of non-intranasal esketamine: A systematic review
    Sanne Y. Smith-Apeldoorn, Maurice Vischjager, Jolien K. E. Veraart, Jeanine Kamphuis, Marije aan het Rot, Robert A. Schoevers · 2022 · Journal of Psychopharmacology
  31. Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach
    Phil Wolfson, Gita Vaid · 2024 · Frontiers in Psychiatry
  32. The science of psychedelic medicine
    Joshua S. Siegel, Conor M. Liston, Ginger E. Nicol, Robin Lester Carhart-Harris, Michael P. Bogenschutz · 2026 · Nature Medicine
  33. Therapy Response Prediction in Major Depressive Disorder: Current and Novel Genomic Markers Influencing Pharmacokinetics and Pharmacodynamics
    Alena A. Shalimova, Victoria S. Babasieva, Vladimir N. Chubarev, Vadim V. Tarasov, Helgi B. Schiöth, Jessica Mwinyi · 2021 · Pharmacogenomics
  34. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
    Alice Lineham, Victor Javier Avila-Quintero, Michael H. Bloch, Jennifer B. Dwyer · 2023 · Journal of Child and Adolescent Psychopharmacology
  35. Ketamine’s acute effects on negative brain states are mediated through distinct altered states of consciousness in humans
    Laura M. Hack, Xue Zhang, Boris Dov Heifets, Trisha M Suppes, Peter van Roessel, Jerome Albert Yesavage, Nancy J. Gray, Rachel A. Hilton, Claire Bertrand, Carolyn I. Rodríguez et al. · 2023 · Nature Communications
  36. Differential role of nitric oxide in the psychedelic symptoms induced by racemic ketamine and esketamine in human volunteers
    Kelly Jonkman, Rutger M. van der Schrier, Monique van Velzen, Leon P.H.J. Aarts, Erik Olofsen, Elise Y. Sarton, Marieke Niesters, Albert Dahan · 2018 · British Journal of Anaesthesia
  37. Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
    Xuepeng Jing, Nicholas R. Hoeh, David Benjamin Menkes · 2023 · Palliative & Supportive Care
  38. Development of New Psychopharmacological Agents for Depression and Anxiety
    Alan F. Schatzberg · 2015 · Psychiatric Clinics of North America
  39. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior
    Lai Fong Chan, Choon Leng Eu, Shean Yih Soh, Thambu Maniam, Zuri Shahidii Kadir, Benedict Tak Wai Chong, Jiann Lin Loo, Shalisah Sharip, VINCENT CHOONG WAI WONG, Tsui Huei Loo et al. · 2018 · Journal of Psychiatric Practice
  40. Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
    Miguel Farinha‐Ferreira, Catarina Miranda‐Lourenço, Chloé Galipeau, Zsolt Lenkei, Ana Maria Sebastião · 2024 · Neuropharmacology
  41. Effects of dopamine and serotonin synthesis inhibitors on the ketamine-, d-amphetamine-, and cocaine-induced locomotor activity of preweanling and adolescent rats: sex differences
    Sanders A. McDougall, Jasmine W. Rios, Matthew G. Apodaca, Ginny I. Park, Nazaret R. Montejano, Jordan A. Taylor, Andrea E. Moran, Jasmine A.M. Robinson, Timothy J. Baum, Angie Teran et al. · 2019 · Behavioural Brain Research
  42. Transient Dose-dependent Effects of Ketamine on Neural Oscillatory Activity in Wistar-Kyoto Rats
    Joshua D. Manduca, Rachel-Karson Thériault, Olivia O. F. Williams, Duncan J. Rasmussen, Melissa L. Perreault · 2020 · Neuroscience
  43. Treatment of dissociative identity disorder: leveraging neurobiology to optimize success
    Purcell, Juliann B., Brand, Bethany, Browne, Heidi A., Chefetz, Richard A., Shanahan, Meghan, Bair, Zoe A., Baranowski, Kim A., Davis, Vona, Mangones, Patricia, Modell, Rebecca L. et al. · 2024 · Expert review of neurotherapeutics
  44. The role of NMDARs in the anesthetic and antidepressant effects of ketamine
    Liang Zhou, Jingjing Duan · 2023 · CNS Neuroscience & Therapeutics
  45. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
    Alice Lineham, Victor Javier Avila-Quintero, Michael H. Bloch, Jennifer B. Dwyer · 2024 · Journal of Child and Adolescent Psychopharmacology
  46. Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome
    Jack D. C. Dahan, David Dadiomov, Tijmen Bostoen, Albert Dahan · 2024 · npj Mental Health Research
  47. Baseline Vitamin B12 and Folate Levels Do Not Predict Improvement in Depression After a Single Infusion of Ketamine
    Nancy B. Lundin, Mark J. Niciu, David A. Luckenbaugh, D. Ionescu, Erica M. Richards, Jennifer Vande Voort, Nancy E. Brutsché, Rodrigo Machado‐Vieira, Carlos A. Zarate · 2014 · Pharmacopsychiatry
  48. Association of the delayed changes in glutamate levels and functional connectivity with the immediate network effects of S-ketamine
    Lena Vera Danyeli, Zümrüt Duygu Şen, Lejla Čolić, Lisa Kurzweil, Sabrina Gensberger‐Reigl, Tamar Macharadze, Florian N. Götting, Alexander Refisch, Thomas Liebe, Tara Chand et al. · 2023 · Translational Psychiatry
  49. Ketamine: Leading us into the future for development of antidepressants
    Flavia Regina Carreno, Daniel J. Lodge, Alan Frazer · 2020 · Behavioural Brain Research
  50. Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
    Raquel Bennett, Christian Yavorsky, GARY L. BRAVO · 2022 · Frontiers in Psychiatry
  51. Experiences of Awe Mediate Ketamine’s Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression
    Julia Aepfelbacher, Benjamin Panny, Rebecca B. Price · 2024 · Biological Psychiatry Global Open Science
  52. Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study)
    Ian Muir Anderson, Andrew Matthew Blamire, Tim Branton, Sabrina Brigadoi, Ross Allan Clark, Darragh Downey, Graham Dunn, Andrew Easton, Rebecca Elliott, Clare E. Elwell et al. · 2017 · Efficacy and Mechanism Evaluation
  53. Antidepressant Effects of Ketamine Are Not Related to 18F-FDG Metabolism or Tyrosine Hydroxylase Immunoreactivity in the Ventral Tegmental Area of Wistar Rats
    Pedro Porto Alegre Baptista, Lisiani Saur, Pamela Brambilla Bagatini, Samuel Greggio, Gianina Teribele Venturin, Sabrina Pereira Vaz, Kelly Ferreira, Juliana Silva Junqueira, Diogo Rizzato Lara, Jaderson Costa DaCosta et al. · 2015 · Neurochemical Research
  54. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial
    Jennifer Lynne Phillips, Sandhaya Norris, Jeanne D. Talbot, Meagan Birmingham, Taylor Hatchard, Abigail Ortiz, Olabisi Owoeye, Lisa A. Batten, Pierre Blier · 2020 · FOCUS The Journal of Lifelong Learning in Psychiatry
  55. Oral ketamine reduces the experience of stress in people with chronic suicidality
    Megan Dutton, Adem Can, Denise A. Beaudequin, Emma Jensen, Monique Jones, Cyrana C. Gallay, Paul Schwenn, Jennifer K. Scherman, Cian Yang, Grace Forsyth et al. · 2022 · Journal of Affective Disorders
  56. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework
    Manon van den Berg, Igor Magaraggia, Rudy Schreiber, Todd M. Hillhouse, Joseph H. Porter · 2022 · Psychopharmacology
  57. Pharmacological modelling of dissociation and psychosis: an evaluation of the Clinician Administered Dissociative States Scale and Psychotomimetic States Inventory during nitrous oxide (‘laughing gas’)-induced anomalous states
    Giulia Piazza, Georges Iskandar, V. Hennessy, Hannah Zhao, K. Walsh, J. McDonnell, D. Terhune, Ravi K. Das, Sunjeev K Kamboj · 2022 · Psychopharmacology
  58. Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression
    Joanna Szarmach, Wiesław Jerzy Cubała, Adam Włodarczyk, Maria Gałuszko‐Węgielnik · 2021 · Medicina
  59. Key considerations in the pharmacological management of treatment-resistant depression
    Mani Yavi, Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate · 2021 · Expert Opinion on Pharmacotherapy
  60. Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test
    Phil Skolnick, Tomasz Kos, Janusz Czekaj, Piotr Popik · 2015 · Acta Neuropsychiatrica
  61. Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice.
    Jesus S. Saavedra, Patrick I. Garrett, Sarah C. Honeycutt, Ashley M. Peterson, J. White, Todd M. Hillhouse · 2020 · Pharmacology, Biochemistry and Behavior
  62. Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study
    Fernanda Palhano-Fontes, Patrícia Cavalcanti-Ribeiro, Kaike Thiê da Costa Gonçalves, Victor Rocha Nóbrega de Almeida, David Cavalcante Barbosa, Marcos André de Araújo Ferreira, Raynara Bolcont, Lara Carvalho Araújo Melo De Souza, Nestor Caetano dos Santos, Eduardo Igor Torquato Cardoso Lopes et al. · 2024 · Journal of Affective Disorders
  63. Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective
    Michele Fornaro, Lubna Kardash, Stefano Novello, Andrea Fusco, Annalisa Anastasia, Domenico De Berardis, Giampaolo Perna, Mauro Giovanni Carta · 2018 · Expert Opinion on Drug Discovery
  64. NMDA Antagonists for Treatment-Resistant Depression
    Nuri B. Farber · 2018 · Handbook of experimental pharmacology
  65. Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review
    JULIA MURIEL KUTNO FREIND, Fernando R. Beserra, Bruno S. Menezes, Daniel C. Mograbi · 2023 · Journal of Psychoactive Drugs
  66. Modulating factors in mood disorders treatment
    Alessandro Serretti · 2023 · International Clinical Psychopharmacology
  67. Genetic Findings in Obsessive–Compulsive Disorder Connect to Brain‐Derived Neurotropic Factor and Mammalian Target of Rapamycin Pathways: Implications for Drug Development
    Marco A. Grados, Hyung Mo Sung, Se-Jin Kim, Siddharth Srivastava · 2014 · Drug Development Research
  68. Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
    David Williamson, Ibrahim Turkoz, Ewa Wajs, Jaskaran B. Singh, Stephane Borentain, Wayne Curtis Drevets · 2022 · The International Journal of Neuropsychopharmacology
  69. Issues encountered in recent attempts to develop novel antidepressant agents
    Alan F. Schatzberg · 2015 · Annals of the New York Academy of Sciences
  70. Corticosterone as a potential confounding factor in delineating mechanisms underlying Ketamine’s rapid antidepressant actions
    Wegman-Points, Lauren, Pope, Brock, Zobel-Mask, Allison, Winter, Lori, Wauson, Eric, Duric, Vanja, Yuan, Li-Lian · 2020 · Frontiers in Pharmacology
  71. Alternatives to ketamine in depression: state-of-the-art and future perspectives
    Luke A. Jelen, Sinéad King, James M. Stone · 2017 · Therapeutic Advances in Psychopharmacology
  72. Dissociative Symptoms and Interoceptive Integration
    Sascha P. Woelk, Sarah N. Garfinkel · 2024 · Current topics in behavioral neurosciences
  73. Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression
    Adrienne Lapidos, Daniela Lopez-Vives, Cortney E. Sera, Elizabeth Ahearn, Erica Vest, Ivana Senic, Jennifer L. Vande Voort, Mark A. Frye, Fernando S. Goes, Eric D. Achtyes et al. · 2022 · Journal of Affective Disorders
  74. Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine or esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial
    Mariana V.F. Echegaray, Rodrigo Paixão Mello, Guilherme Moreira Magnavita, Gustavo Carneiro-Gomes Leal, Fernanda S. Correia‐Melo, Ana Paula Jesus‐Nunes, Flávia Vieira, Igor Dórea Bandeira, Ana Teresa Caliman‐Fontes, Manuela Telles et al. · 2023 · Trends in Psychiatry and Psychotherapy
  75. Acute Dissociation and Ketamine’s Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial
    Sumra Sajid, H. Galfalvy, J. Keilp, A. Burke, J. Mann, Michael F. Grunebaum · 2024 · International Journal of Neuropsychopharmacology
  76. Current Trends in Identifying Rapidly Acting Treatments for Depression
    D. Ionescu, G. Papakostas · 2016 · Current Behavioral Neuroscience Reports
  77. Nasal respiration is necessary for ketamine-dependent high frequency network oscillations and behavioral hyperactivity in rats
    Jacek Wróbel, Władysław Średniawa, Gabriela Jurkiewicz, Jarosław Żygierewicz, Daniel Krzysztof Wojcik, Miles A. Whittington, Mark Jeremy Hunt · 2020 · Scientific Reports
  78. Enantioselective inhibition of <scp>d</scp>‐serine transport by (<scp><i>S</i></scp>)‐ketamine
    Singh, Nagendra S, Bernier, Michel, Camandola, Simonetta, Khadeer, Mohammed A, Moaddel, Ruin, Mattson, Mark P, Wainer, Irving W · 2015 · British Journal of Pharmacology
  79. Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
    Daniella Batievsky, Michelle D. Weiner, Shari B. Kaplan, Michael E. Thase, Domenick Nicholas Maglione, Denise Christina Vidot · 2023 · Frontiers in Pain Research
  80. Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms
    Adam Włodarczyk, Alicja Dywel, Wiesław Jerzy Cubała · 2023 · Pharmaceuticals
  81. Kétamine, psilocybine, et antidépresseurs d'action rapide : de nouvelles promesses pour la psychiatrie?
    Hugo Bottemanne, Anne Claret, Philippe Fossati · 2020 · L Encéphale
  82. Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
    Lorena Catarina Del Sant, Luciana Maria Sarin, Ana Cecília Lucchese, Eric Thomas Paiva Magalhães, Marco Aurélio Tuena, Carolina Nakahira, José Alberto Del Porto, Acioly L.T. Lacerda, Jair de Jesus Mari · 2022 · Pharmaceuticals
  83. The Effects of Psychotherapy on Single and Repeated Ketamine Infusion(s) Therapy for Treatment-Resistant Depression: The Convergence of Molecular and Psychological Treatment
    Sofia Sakopoulos, McWelling Todman · 2025 · International Journal of Molecular Sciences
  84. Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
    Alan K. Davis, Meghan A. DellaCrosse, Nathan D. Sepeda, Adam W. Levin, Mary P Cosimano, Hillary Shaub, Taylor Washington, Peter M. Gooch, Shoval Gilead, Skylar J. Gaughan et al. · 2025 · Journal of Psychedelic Studies
  85. Factors Associated with Antidepressant Effects of Ketamine: A Reanalysis of Double-Blind Randomized Placebo-Controlled Trial of Intravenous Ketamine for Treatment-Resistant Depression
    Kengo Yonezawa, Hiroyuki Uchida, Taisuke Yatomi, Yohei Ohtani, Kie Nomoto‐Takahashi, Shinichiro Nakajima, Masaru Mimura, Hideaki Tani · 2023 · Pharmacopsychiatry
  86. The link between childhood trauma and dissociation in frequent users of classic psychedelics and dissociatives
    Sascha B. Thal, Judith Karina Daniels, Henrik Jungaberle · 2019 · Journal of Substance Use
  87. NMDA receptor antagonists traxoprodil and lanicemine improve hippocampal-prefrontal coupling and reward-related networks in rats
    Robert Becker, Natalia Gass, Lothar Kußmaul, Bernhard Schmid, Stefan Scheuerer, David Schnell, Cornelia Dorner‐Ciossek, Wolfgang Weber‐Fahr, Alexander Sartorius · 2019 · Psychopharmacology
  88. Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression
    Adam Włodarczyk, Wiesław Jerzy Cubała, Maria Gałuszko‐Węgielnik, Joanna Szarmach · 2021 · Therapeutic Advances in Psychopharmacology
  89. Core Concepts Involving Adverse Psychotropic Drug Effects
    Joseph F. Goldberg, Carrie L. Ernst · 2016 · Psychiatric Clinics of North America
  90. Psychometric properties of the 23-Item Clinician Administered Dissociative States Scale (CADSS) in a psychological trauma population
    J. Douglas Bremner, David Williamson, Viola Vaccarino · 2024 · Journal of Affective Disorders
  91. Psychothérapie augmentée par la kétamine (KAP) dans les troubles de l’humeur : mode d’emploi
    Hugo Bottemanne, Antoine Baldacci, C. Muller, A. Boyreau, Anne Claret · 2021 · L Encéphale
  92. Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial
    Marco Aurélio Cigognini, Alia Garrudo Guirado, Denise van de Meene, Mônica Andréia Schneider, Mônica Sarah Salomon, Vinicius Santana de Alexandria, Juliana Pisseta Adriano, Ana Maria Thaler, Fernando dos Santos Fernandes, Adriana Munhoz Carneiro et al. · 2022 · Frontiers in Psychiatry
  93. Recent Developments in Pharmacotherapy of Depression: Bench to Bedside
    Mujeeb Uddin Shad · 2023 · Journal of Personalized Medicine
  94. Differential effectiveness between Ketamine and Esketamine: the predictive role of dissociative features. A treatment-resistant depression case
    Nicola Ragone, Barbara Barbini, Carolina Passani, Federico Seghi, Cristina Colombo · 2023 · International Clinical Psychopharmacology
  95. Regarding the Transpersonal Nature of Ketamine Therapy: An Approach to the Work
    Jeffrey Becker · 2014 · International Journal of Transpersonal Studies
  96. The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
    Dongsun Park, Gwangho Lee, Won-Gyu Lee, B.S. Kim, Yoonji Lee, Ji‐Woon Kim · 2025 · Molecular Psychiatry
  97. Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
    Kallol Bera, Loren L. Looger, Alex Proekt, Joseph Cichon · 2025 · The Neuroscientist
  98. Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
    Wen Wen, Wenjing Zhao, Xing Xia, Xiangjun Duan, Liang Zhang, Duomao Lin, Zeyou Qi, Sheng Wang, Mingxin Gao, Changcheng Liu et al. · 2024 · Pharmacology Biochemistry and Behavior
  99. Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices
    Kaike Thiê da Costa Gonçalves, Vagner Deuel de Oliveira Tavares, Maria Luiza de Morais Barros, Aldielyson Jorge Cavalcante de Brito, Patrícia Cavalcanti-Ribeiro, Fernanda Palhano-Fontes, Marcelo Falchi-Carvalho, Emerson Arcoverde, RAFAEL GUIMARÃES DOS SANTOS, Jaime E. C. Hallak et al. · 2024 · European Archives of Psychiatry and Clinical Neuroscience
  100. Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report
    Louis Chevalier, Samuel Bulteau, Louis Cheval, Jalal Charron, Anne Sauvaget, Andrew Laurin · 2024 · International Clinical Psychopharmacology